{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:11:00Z","timestamp":1780409460300,"version":"3.54.1"},"reference-count":32,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T00:00:00Z","timestamp":1617494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Context<\/jats:title><jats:p>A lack of consensus remains about the relative importance of insulin\u2010like growth factor\u20101 (IGF\u20101) and growth hormone (GH) in predicting adverse outcomes in patients with acromegaly.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To describe the differing association between IGF\u20101 and GH and major disease outcomes in acromegaly.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Retrospective cohort study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>United Kingdom National Health Service patients with acromegaly who had an IGF\u20101 and\/or a GH measurement recorded following diagnosis, prior to December 2019.<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements<\/jats:title><jats:p>A composite endpoint including all\u2010cause mortality (ACM), type 2 diabetes (DM), major adverse cardiovascular events (MACE) or cancer was the primary outcome. These outcomes were also analysed individually. Follow\u2010up period was capped at 5\u00a0years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A maximum of 417 cases and 332 cases were eligible for the IGF\u20101 and GH analyses, respectively, comprising 1041.5 and 938.9\u00a0years of follow\u2010up. There was a direct association between increased IGF\u20101 concentration and adjusted event risk for the composite endpoint (hazard ratio [HR]\u00a0=\u00a01.2; 95% confidence interval [CI]\u00a0=\u00a01.02\u20101.5); in GH, the HR was 1.1 (1.0\u20101.2). For the individual endpoints in relation to IGF\u20101 level, the HRs were ACM (1.2; 0.93\u20101.5), MACE (1.2; 0.64\u20102.1), DM (1.53; 1.09\u20102.2) and cancer (1.3; 0.95\u20101.7). For GH, the HRs were ACM (1.1; 0.97\u20101.2), MACE (0.99; 0.73\u20101.3), DM (1.1; 0.99\u20101.2) and cancer (0.90; 0.66\u20101.2).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this contemporary data set with extended follow\u2010up, IGF\u20101 and GH concentrations showed an association with major adverse outcomes from acromegaly.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cen.14468","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T13:09:46Z","timestamp":1616418586000},"page":"143-152","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Insulin\u2010like growth factor\u20101, growth hormone and disease outcomes in acromegaly: A population study"],"prefix":"10.1111","volume":"95","author":[{"given":"Melissa","family":"Thomas","sequence":"first","affiliation":[{"name":"Pharmatelligence Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Berni","sequence":"additional","affiliation":[{"name":"Pharmatelligence Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Jenkins\u2010Jones","sequence":"additional","affiliation":[{"name":"Pharmatelligence Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Wensley","sequence":"additional","affiliation":[{"name":"Pfizer Limited Tadworth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris D.","family":"Poole","sequence":"additional","affiliation":[{"name":"Pharmatelligence Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig J.","family":"Currie","sequence":"additional","affiliation":[{"name":"Pharmatelligence Cardiff UK"},{"name":"Division of Population Medicine School of Medicine Cardiff University Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Brownrigg","sequence":"additional","affiliation":[{"name":"Pfizer Limited Tadworth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ayuk","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Hospital Birmingham Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1165-9092","authenticated-orcid":false,"given":"D. Aled","family":"Rees","sequence":"additional","affiliation":[{"name":"Neuroscience and Mental Health Research Institute School of Medicine Cardiff University Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,4,4]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-016-0754-x"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2009-0033"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-011-0308-1"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1191"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0267"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031199"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031584"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1257"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2007.02836.x"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2004.01982.x"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09588-z"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1381"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1510439"},{"key":"e_1_2_10_16_1","first-page":"2730","article-title":"Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group","volume":"83","author":"Orme SM","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.10.3419"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-032041"},{"key":"e_1_2_10_19_1","first-page":"78","article-title":"IGF\u2010I and mortality in patients with acromegaly","volume":"28","author":"Strasburger CJ","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0084"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0106"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2670"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-017-0838-7"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-10-1050"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-013-0471-7"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0253"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-012-0396-6"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0657-2"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2019.02.001"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-309573"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0255"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2372"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz096"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen.14468","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cen.14468","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen.14468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T23:51:44Z","timestamp":1693353104000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cen.14468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,4]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1111\/cen.14468"],"URL":"https:\/\/doi.org\/10.1111\/cen.14468","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,4]]},"assertion":[{"value":"2021-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}